BNP Paribas Financial Markets
KPTI icon

BNP Paribas Financial Markets’s Karyopharm Therapeutics KPTI Stock Holding History

BNP Paribas Financial Markets’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$468 Buy
84
+2
+2% +$15 ﹤0.01% 5550
2025
Q4 		$604 Hold
82
– – ﹤0.01% 5463
2025
Q3 		$536 Sell
82
-29,555
-100% -$159K ﹤0.01% 5305
2025
Q2 		$128K Buy
29,637
+676
+2% +$3.32K ﹤0.01% 3934
2025
Q1 		$108K Sell
28,961
-58,632
-67% -$501K ﹤0.01% 4010
2024
Q4 		$889K Sell
87,593
-44,564
-34% -$539K ﹤0.01% 2907
2024
Q3 		$1.65M Sell
132,157
-19,456
-13% -$242K ﹤0.01% 2159
2024
Q2 		$1.97M Buy
151,613
+33,362
+28% +$552K ﹤0.01% 1924
2024
Q1 		$2.68M Buy
118,251
+305
+0.3% +$5.35K ﹤0.01% 1871
2023
Q4 		$1.53M Buy
117,946
+7,219
+7% +$97.3K ﹤0.01% 2129
2023
Q3 		$2.23M Buy
110,727
+79,987
+260% +$1.8M ﹤0.01% 1817
2023
Q2 		$825K Buy
30,740
+6,100
+25% +$263K ﹤0.01% 2318
2023
Q1 		$1.44M Sell
24,640
-3,601
-13% -$178K ﹤0.01% 2068
2022
Q4 		$1.44M Sell
28,241
-22,594
-44% -$1.57M ﹤0.01% 1955
2022
Q3 		$4.16M Buy
50,835
+11,882
+31% +$888K 0.01% 1464
2022
Q2 		$2.64M Buy
38,953
+38,383
+6,734% +$3.52M ﹤0.01% 1593
2022
Q1 		$63K Sell
570
-392
-41% -$48.9K ﹤0.01% 3504
2021
Q4 		$92.7K Sell
962
-30,254
-97% -$3.02M ﹤0.01% 3617
2021
Q3 		$2.73M Buy
31,216
+5,034
+19% +$523K ﹤0.01% 1685
2021
Q2 		$4.05M Buy
26,182
+25,594
+4,353% +$3.71M 0.01% 1401
2021
Q1 		$92.8K Sell
588
-5,764
-91% -$1.21M ﹤0.01% 3391
2020
Q4 		$1.47M Buy
6,352
+5,269
+487% +$1.22M ﹤0.01% 1782
2020
Q3 		$237K Buy
1,083
+375
+53% +$91.7K ﹤0.01% 2675
2020
Q2 		$201K Sell
708
-1,771
-71% -$524K ﹤0.01% 2490
2020
Q1 		$714K Buy
2,479
+2,016
+435% +$556K ﹤0.01% 2139
2019
Q4 		$133K Sell
463
-81
-15% -$17.6K ﹤0.01% 3154
2019
Q3 		$78.6K Buy
544
+182
+50% +$24.7K ﹤0.01% 3247
2019
Q2 		$32.5K Sell
362
-316
-47% -$25.4K ﹤0.01% 3682
2019
Q1 		$59.4K Buy
+678
New +$75.2K ﹤0.01% 3414
2018
Q4 		– Sell
-106
Closed -$17.9K – 4244
2018
Q3 		$27.2K Hold
106
– – ﹤0.01% 3295
2018
Q2 		$27.1K Sell
106
-420
-80% -$104K ﹤0.01% 3374
2018
Q1 		$106K Buy
526
+51
+11% +$10.2K ﹤0.01% 3147
2017
Q4 		$68.4K Buy
475
+185
+64% +$29.7K ﹤0.01% 3503
2017
Q3 		$47.8K Sell
290
-6
-2% -$859 ﹤0.01% 3170
2017
Q2 		$40.2K Buy
296
+230
+348% +$34K ﹤0.01% 3308
2017
Q1 		$12.8K Sell
66
-24
-27% -$3.85K ﹤0.01% 3134
2016
Q4 		$12.6K Sell
90
-27
-23% -$3.65K ﹤0.01% 3355
2016
Q3 		$17.1K Buy
117
+55
+89% +$6.61K ﹤0.01% 2974
2016
Q2 		$6.24K Buy
+62
New +$8.05K ﹤0.01% 3155
2016
Q1 		– Sell
-306
Closed -$60.7K – 2885
2015
Q4 		$60.7K Sell
306
-37
-11% -$8.01K ﹤0.01% 2673
2015
Q3 		$54.1K Buy
343
+215
+168% +$57.5K ﹤0.01% 2798
2015
Q2 		$52.3K Buy
128
+108
+540% +$46.7K ﹤0.01% 2468
2015
Q1 		$9.03K Buy
+20
New +$8.62K ﹤0.01% 2813
2014
Q4 		– Sell
-58
Closed -$30.6K – 2619
2014
Q3 		$30.6K Buy
58
+56
+2,800% +$31.6K ﹤0.01% 2887
2014
Q2 		$1.58K Hold
2
– – ﹤0.01% 3229
2014
Q1 		$644 Sell
2
-4
-67% -$2.03K ﹤0.01% 2983
2013
Q4 		$2.2K Buy
+6
New +$1.66K ﹤0.01% 3619

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

BNP Paribas Financial Markets's KPTI Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Karyopharm Therapeutics (KPTI) stake by 2.4% in Q1 2026, buying an estimated $15 and bringing the position to 84 shares worth $468. The position accounts for ﹤0.01% of the portfolio, ranked #5550.

BNP Paribas Financial Markets first reported a position in KPTI in Q4 2013 and has held it in 47 quarters since. The position peaked at $4.16M in Q3 2022. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • BNP Paribas Financial Markets held 84 shares of Karyopharm Therapeutics worth $468 as of Q1 2026.
  • BNP Paribas Financial Markets bought 2 Karyopharm Therapeutics shares in Q1 2026, an estimated $15.
  • Karyopharm Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5550 holding.
  • BNP Paribas Financial Markets first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 47 quarters since.
  • BNP Paribas Financial Markets's Karyopharm Therapeutics position peaked at $4.16M in Q3 2022.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.